CITA Biomedical Names Michel A. Sucher, M.D., Chief Medical Advisor.

Business Editors

BEVERLY HILLS, Calif.--(BUSINESS WIRE)--July 17, 2001

Sucher to Chair CITA's Scientific and Medical Advisory Committee;

Manage Business Development and Marketing

CITA Biomedical Inc. (OTCBB:DTOX), a growing leader in the treatment of addiction dependency, today announced that it has named Michel (Mike) A. Sucher, M.D. FASAM, as the company's chief medical advisor and chairman of CITA's Scientific and Medical Advisory Committee (SAMAC).

Sucher is responsible for providing clinical direction and consultation to CITA-licensed treatment centers as well as directing corporate business development and marketing.

Sucher brings to CITA 15 years of medical consulting and marketing experience concentrated in the drug and alcohol addiction treatment arena, especially as it relates to the impaired professional treatment community -- a key area of focus for CITA.

"I am very excited about joining the premier provider of Ultra Rapid Opiate Detoxification and other innovative addiction treatment services," said Sucher. "I believe that working with the CITA team, we can make this valuable procedure available to many people who have been unable to complete traditional detoxification successfully. UROD is a safe and cost-effective solution."

Sucher most recently served as senior vice president and chief medical officer for Rural/Metro Corp. in Scottsdale, Ariz., where he developed an innovative coding system for ambulance medical conditions -- a program for the integration of medical call centers and medical transportation -- and oversaw marketing and business development. He also had responsibility for the Latin American Region, including physician services in Argentina and Bolivia.

Sucher currently serves as the medical director of the monitoring programs for the Arizona Board of Medical Examiners, the Arizona State Board of Dental Examiners and the State Bar of Arizona. He is also a consultant to many other health-care regulatory boards in the State of Arizona.

Lastly, he is the medical director of the residential chemical dependency treatment program at the Banner Behavioral Health Center in Scottsdale, which also serves as a treatment site for many CITA patients.

Sucher is board certified by the American Board of Emergency Medicine and certified by the American Society of Addiction Medicine. Also, Sucher is an active member of professional societies, such as the American College of Emergency Physicians, the American College of Physician Executives, the American Society of Addiction Medicine, the Arizona Medical Association and the National Association of EMS Physicians.

Sucher has delivered nearly 30 lectures, nationally, and currently holds numerous teaching positions throughout Arizona, including instructor in medicine at the Mayo Medical School, Assistant Clinical Professor at the Midwestern University Arizona College of Osteopathic Medicine and is clinical faculty for the emergency medicine residency program at Maricopa Medical Center in Phoenix.

In addition, Sucher has been published in various publications, which include an abstract in the Annals of Emergency Medicine, the National Association of EMS Physician News, Scope Magazine as well as a chapter on impaired physicians in the American College of Emergency Physicians Textbook.

Born in Detroit, Sucher holds a bachelor's degree in biology and a medical degree from Wayne State University. He held a rotating internship position at Sinai Hospital of Detroit and residency in diagnostic radiology at Indiana University Medical Center.

"As CITA continues to grow and rapidly licenses more treatment centers, worldwide, it is imperative to have a highly qualified addiction treatment expert in the role of chief medical advisor to help move our business forward," said Joseph Dunn, president and CEO of CITA Biomedical.

"With his impressive background and credentials, we are extremely pleased to have Dr. Sucher fill this important position on the CITA team. Also, Dr. Sucher's medical experience in South America will be extremely valuable in helping CITA break into new markets, taking the UROD(R) treatment method into the mainstream."

About UROD(R)

Performed by CITA- and state-board certified physicians in CITA-licensed treatment centers, the UROD(R) (Ultra Rapid Opiate Detoxification) process is designed to purge opiates from the body with its unique pharmaceutical formula of FDA-approved medications. CITA also offers a comprehensive aftercare program -- FIT(SM) (Flexible Intensity Treatment). After the UROD(R) procedure, the patient embarks on a six-month medication and therapy regimen.

About CITA Biomedical

CITA Biomedical Inc., with headquarters in Beverly Hills, focuses on investigation and treatment of addiction. The company holds a U.S. patent for its successful UROD(R)(Ultra Rapid Opiate Detoxification) treatment method. CITA grows its business through internal expansion and seeks compatible, competitive and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical Inc. has two operating divisions -- CITA Americas Inc. and CubeCentral.com Inc. For more information, visit www.citabio.com.

UROD is a registered trademark of CITA Biomedical Inc. FIT is a service mark of CITA Biomedical Inc.

The information contained in this news release includes forward-looking statements. Forward-looking statements include declarations concerning plans, objectives, goals, strategies, future events and/or performance, and underlying assumptions and other statements which are other than statements of historical facts. Forward-looking statements usually contain the words "estimate," "anticipate," "believe," "expect" and other similar expressions that involve risks and uncertainties. These risks and uncertainties include, but are not limited to, the company's status as a start-up enterprise with uncertain profitability, its need for significant capital, limited facilities, competition, uncertainty as to market acceptance of its services, and the protection of its intellectual property. The company's actual results could differ materially from those expressed or implied in any forward-looking statements.